| Product NDC: | 55154-8250 |
| Proprietary Name: | BUDEPRION |
| Non Proprietary Name: | BUPROPION HYDROCHLORIDE |
| Active Ingredient(s): | 150 mg/1 & nbsp; BUPROPION HYDROCHLORIDE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 55154-8250 |
| Labeler Name: | Cardinal Health |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA075913 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20040322 |
| Package NDC: | 55154-8250-4 |
| Package Description: | 100 POUCH in 1 CARTON (55154-8250-4) > 1 TABLET, EXTENDED RELEASE in 1 POUCH (55154-8250-6) |
| NDC Code | 55154-8250-4 |
| Proprietary Name | BUDEPRION |
| Package Description | 100 POUCH in 1 CARTON (55154-8250-4) > 1 TABLET, EXTENDED RELEASE in 1 POUCH (55154-8250-6) |
| Product NDC | 55154-8250 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | BUPROPION HYDROCHLORIDE |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20040322 |
| Marketing Category Name | ANDA |
| Labeler Name | Cardinal Health |
| Substance Name | BUPROPION HYDROCHLORIDE |
| Strength Number | 150 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |